Blog
RSS FeedPosted by Michael Wonder on 05 Aug 2015
Labour pledges cancer therapy fund
A new fund to pay for innovative cancer drugs, surgery and radiotherapy would be set up if Labour comes to ...
Posted by Michael Wonder on 05 Aug 2015
NICE draft guidance recommends a treatment for prostate cancer
In final draft guidance published today, NICE has recommended degarelix (Firmagon, Ferring Pharmaceuticals), as an option for treating advanced hormone dependent prostate ...
Posted by Michael Wonder on 05 Aug 2015
AZ pulls Lynparza's application for CDF funding
AstraZeneca has withdrawn an application to get its first-in-class ovarian cancer therapy Lynparza (olaparib) funded by the Cancer Drugs Fund ...
Posted by Michael Wonder on 05 Aug 2015
Survey highlights oncologist's dismay over CDF cuts
Seventy-nine percent of oncologists taking part in a survey commissioned by Sanofi feel that cuts to England’s Cancer Drugs Fund ...
Posted by Michael Wonder on 05 Aug 2015
NHS England hands over Cancer Drugs Fund remit to NICE
After five years of by-passing NICE, England's Cancer Drugs Fund will now be managed by the health technology assessor as ...
Posted by Michael Wonder on 05 Aug 2015
Novartis drug struck off cancer drugs fund
Novartis' Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can ...
Posted by Michael Wonder on 05 Aug 2015
Cuts to cancer treatments announced
Twenty-five different cancer treatments will no longer be funded by the NHS in England, health chiefs have announced. ...
Posted by Michael Wonder on 05 Aug 2015
NICE issues preliminary recommendations on earlier treatment with abiraterone acetate for prostate cancer
In draft guidance published today NICE has not recommended abiraterone for prostate cancer which has spread in people whose first treatment has ...
Posted by Michael Wonder on 05 Aug 2015
Merck cancer drug is first approved under UK early access scheme
Merck & Co's cancer drug Keytruda, which works by boosting the immune system but has yet to be licensed in ...
Posted by Michael Wonder on 05 Aug 2015
NICE issues final draft guidance recommending enzalutamide for prostate cancer
People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the ...
Posted by Michael Wonder on 05 Aug 2015
Costly cancer drugs face chop from CDF
Proposed changes to the way the Cancer Drugs Fund is run in England are to go ahead so that, for ...
Posted by Michael Wonder on 05 Aug 2015
Eisai confirms life-extending breast cancer treatment Halaven (eribulin) to remain on Cancer Drugs Fund pending reconsideration
Eisai today announces that Halaven (eribulin) will remain on the National Cancer Drugs Fund (NCDF) pending reconsideration by the NCDF panel. ...
Posted by Michael Wonder on 05 Aug 2015
Cancer Drugs Fund 'costly mistake' as re-evaluation begins
An important week for the future of the Cancer Drugs Fund has begun as NHS England starts its re-evaluation of ...
Posted by Michael Wonder on 05 Aug 2015
CDF to revisit delisting of Lilly's Alimta
Lilly’s appeal against the Cancer Drugs Fund’s decision to delist its lung cancer drug Alimta (pemetrexed) has been upheld. ...
Posted by Michael Wonder on 05 Aug 2015
NICE recommends another new treatment for lung cancer
People with lung cancer whose tumours test positive for a mutation will now have access to a third targeted treatment. NICE ...